Fig. 4. SF1126 is more potent than other PI3K-BRD4 inhibitors in killing CRC cells. HT-29 cells (A and B) or primary human colon cancer cells ("pri-Can-2", C and D) were treated with 5 μM of SF1126, LY294002 ("LY"), JQ1, or LY plus JQ1. Cell viability and apoptosis were tested by the MTT assay (A and C) and TUNEL fluorescence intensity assay (B and D), respectively. Stable HT-29 cells, with Akt1 shRNA plus BRD shRNA ["sh-Akt1+BRD4"] or scramble control shRNA ("sh-C"), were treated with/without SF1126 (5 μM) or LY294002 (5 μM) plus JQ1 (5 μM) for the indicated times; expression of the listed proteins are shown (E). Cell viability (F) and apoptosis (G) were tested similarly. *p< 0.05 vs. the "C" group (A-D). ^# p< 0.05 vs."SF1126" treatment (A-D). *p< 0.05 vs. "sh-C" cells (F and G).*p< 0.05 vs. untreated "sh-Akt1+BRD4" cells (F and G). The experiments were repeated three times, with similar results obtained.